Lymphedema Prevention Program
Help Prevent Cancer-Related Lymphedema with a 30-second Test
Lymphedema affects up to 10 million Americans – more than muscular dystrophy, MS, ALS, Parkinsons and AIDS combined1. Early detection of lymphedema using SOZO® with L-Dex®, combined with at-home compression treatment, is shown to reduce lymphedema progression by 95%2.
Now is the Time to Prevent Lymphedema
In the past, the onset of lymphedema was too difficult to detect using standard measurement techniques. Now, SOZO® with L-Dex® technology aids in detecting lymphedema at the subclinical level, or Stage 0, before visible swelling and the condition is irreversible.
L-Dex® Precisely Measures Body Fluid in 30 Seconds
L-Dex® measures and assesses fluid buildup in an at-risk limb compared to a healthy limb to help detect early signs of lymphedema. It uses noninvasive bioimpedance spectroscopy (BIS), which is capable of detecting fluid changes as small as 2.4 tablespoons (36ml) and takes less than 30 seconds to complete.
Facts About Lymphedema
What is Lymphedema?
Cancer-related lymphedema, also called secondary lymphedema, is a condition that can cause swelling in the body due to the build-up of fluid in soft body tissues when the lymph system is damaged or blocked.
What Causes Lymphedema?
Secondary lymphedema is most frequently caused by cancer or cancer treatments such as surgery, radiation, and chemotherapy. If left untreated, it can become a life-long condition.
How Common is Lymphedema?
50% of cancer patients are at risk for limb lymphedema3-5. 1 in 3 will develop lymphedema4,5.
When Do Patients Develop Lymphedema?
Lymphedema can occur at any time after cancer treatment. 75% of patients who develop lymphedema do so within 3 years after surgery6
How to Prevent Lymphedema after Cancer Treatment
Early Detection & Treatment are Critical
By the time patients experience lymphedema symptoms, it may be too late to reverse the condition. Early detection of lymphedema at the subclinical level before any swelling is visible, is critical.
Early Detection of Lymphedema
SOZO®with L-Dex®delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds
Preventing Lymphedema Progression
Early detection of fluid accumulation coupled with standard, at-home compression treatment has been shown to reduce lymphedema progression by 95%2
Together, We Can End Cancer-Related Lymphedema
Cancer Surgeons
Surgeons are uniquely positioned to identify lymphedema patients early and treat the condition through a Lymphedema Prevention Program
Oncology Directors
Oncology Service Line Directors can attract and retain more patients by providing the specialized, comprehensive care lymphedema patients expect
Cancer Care Teams
By following a proven lymphedema prevention protocol, Cancer Care Teams can deliver the prompt treatment needed to prevent lymphedema from progressing
Cancer Patients & Survivors
Learn more about cancer-related lymphedema, how to prevent it from progressing, and where to find clinics and physicians who offer SOZO® with L-Dex®
Prevent Lymphedema with 3 Simple Steps
Test. Trigger. Treat.TM
A Lymphedema Prevention Program follows three steps to find early signs of lymphedema and to stop it from getting worse.
1. Test
Establish a baseline L-Dex® score upon cancer diagnosis and test periodically after cancer surgery
2. Trigger
Evaluate increases above the L-Dex® baseline, recommended at 6.5 or above
3. Treat
Apply at-home compression treatment to reduce lymphedema progression
SOZO® with L-Dex Helps Detect Subclinical Lymphedema
SOZO®, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, incorporates L-Dex® technology to aid in the assessment of secondary lymphedema and delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds.
Together, We Can End Cancer-Related Lymphedema
Contact us to learn about SOZO® with L-Dex and the benefits of supporting a Lymphedema Prevention Program.
References
- https://lymphaticnetwork.org/treating-lymphedema. Accessed September 12, 2019.
- Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol 2019; https://doi.org/10.1245/s10434-019-07344-5.
- American Cancer Society’s Cancer Facts and Figures, 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
- Shaitelman SF, et al. Recent Progress in the Treatment and Prevention of Cancer-Related Lymphedema. CA Cancer J Clin. 2015;00:00–00.
- Brown JC, et al. The Prevalence of Lymphedema Symptoms among Long-Term Cancer Survivors with or at-risk for Lower Limb Lymphedema. Am J Phys Med Rehabil. 2013 March ; 92(3): 223–231. doi:10.1097/PHM.0b013e31826edd97.
- Herd-Smith, A., et al., Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer, 2001. 92(7): p. 1783-7
General or Sales Inquiries
enquiries@impedimed.com
1 +61-7-3860-3700
U.S. Headquarters
5900 Pasteur Ct.
Ste. 125
Carlsbad, CA 92008 USA
+1-877-BIS-0111 or
+1-877-247-0111 (Toll Free)
Phone: +1-760-585-2100
Fax: +1-760-804-9245
info@impedimed.com
European Office
Registered Office
Unit 1
50 Parker Court
Pinkenba, QLD 4008 Australia
Phone: + 61-7-3860-3700
Fax: + 61-7-3260-1225
Free call: 1-800-638-477
enquiries@impedimed.com